The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
Open accessAbstract
Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for patient-specific cell-based organ repair strategies. However, their generation and subsequent differentiation into specific cells or tissues entail cell line-specific manufacturing challenges and form a lengthy process that precludes acute treatment modalities. These shortcomings could be overcome by using prefabricated allogeneic cell or tissue products, but the vigorous immune response against histo-incompatible cells has prevented the successful implementation of this approach. Here we show that both mouse and human iPSCs lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed. These hypoimmunogenic iPSCs retain their pluripotent stem cell potential and differentiation capacity. Endothelial cells, smooth muscle cells, and cardiomyocytes derived from hypoimmunogenic mouse or human iPSCs reliably evade immune rejection in fully MHC-mismatched allogeneic recipients and survive long-term without the use of immunosuppression. These findings suggest that hypoimmunogenic cell grafts can be engineered for universal transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These gene-edited iPSCs could differentiate into endothelial cells and cardiomyocytes that demonstrated long-term survival in humanized mouse models without any immunosuppression.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [118]
The cited source says what the claim attributes to it.
In the citing paper
“Overexpression of CD47 has also been successfully implemented to mitigate innate immune responses after HLA deletion.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature reviews. Immunology · doi:10.1038/nri2017 · Cited by 1,393
Humanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1
Melkus, M. W., Estes, J. D., Padgett‐Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., Wege, A. K., Haase, A. T., & Garcia, J. V. (2006) · Nature Medicine · doi:10.1038/nm1431 · Cited by 653
Self-citationHLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639
Fetomaternal immune cross-talk and its consequences for maternal and offspring's health
Arck, P., & Hecher, K. (2013) · Nature Medicine · doi:10.1038/nm.3160 · Cited by 609
Wunderlich, M., Chou, F.-S., Link, K. A., Mizukawa, B., Perry, R. L., Carroll, M., & Mulloy, J. C. (2010) · Leukemia · doi:10.1038/leu.2010.158 · Cited by 415
Chang, C., Fontes, J., Peterlin, M., & Flavell, R. (1994) · Journal of Experimental Medicine · doi:10.1084/jem.180.4.1367 · Cited by 352
Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marbán, E., Aßmus, B., Henry, T. D., Traverse, J. H., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304346 · Cited by 313
Billerbeck, E., Barry, W. T., Mu, K., Dorner, M., Rice, C. M., & Ploß, A. (2011) · Blood · doi:10.1182/blood-2010-08-301507 · Cited by 305
Quality cell therapy manufacturing by design
Lipsitz, Y. Y., Timmins, N. E., & Zandstra, P. (2016) · Nature Biotechnology · doi:10.1038/nbt.3525 · Cited by 287
Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells.
Hou, S., Doherty, P. C., Zijlstra, M., Jaenisch, R., & Katz, J. M. (1992) · Journal of Immunology · doi:10.4049/jimmunol.149.4.1319 · Cited by 271
An emerging consensus on cardiac regeneration
van Berlo, J. H., & Molkentin, J. D. (2014) · Nature Medicine · doi:10.1038/nm.3764 · Cited by 252
Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure
Fisher, S. A., Doree, C. J., Mathur, A., & Martin‐Rendon, E. (2015) · Circulation Research · doi:10.1161/circresaha.116.304386 · Cited by 202
Wang, D., Quan, Y., Yan, Q., Morales, J. E., & Wetsel, R. A. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0049 · Cited by 187
Self-citationGlobal position paper on cardiovascular regenerative medicine
Fernández‐Avilés, F., y, R. S.-R., Climent, A. M., Badimón, L., Bolli, R., Charron, D. J., Fuster, V., Janssens, S. P., Kastrup, J., Kim, H.-S., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx248 · Cited by 162
Kawamura, T., Miyagawa, S., Fukushima, S., Maeda, A., Kashiyama, N., Kawamura, A., Miki, K., Okita, K., Yoshida, Y., Shiina, T., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.01.012 · Cited by 145
Elsner, L., Muppala, V., Gehrmann, M., Lozano-Kühne, J., Malzahn, D., Bickeböller, H., Brunner, E., Zientkowska, M., Herrmann, T., Walter, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5523 · Cited by 142
Dressel, R., Nolte, J., Elsner, L., Novota, P., Guan, K., Streckfuß‐Bömeke, K., Hasenfuss, G. P., Jaenisch, R., & Engel, W. (2010) · The FASEB Journal · doi:10.1096/fj.09-134957 · Cited by 96
Meta-Analysis of Stem Cell Therapy in Chronic Ischemic Cardiomyopathy
Kandala, J., Upadhyay, G. A., Pokushalov, E. A., Wu, S. M., Drachman, D. E., & Singh, J. P. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.03.021 · Cited by 81
Diecke, S., Lu, J., Lee, J., Termglinchan, V., Kooreman, N. G., Burridge, P. W., Ebert, A., Churko, J. M., Sharma, A., Kay, M. A., et al. (2015) · Scientific Reports · doi:10.1038/srep08081 · Cited by 62
Zhao, L., Teklemariam, T., & Hantash, B. M. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.08.004 · Cited by 60
Kruse, V., Hamann, C., Monecke, S., Cyganek, L., Elsner, L., Hübscher, D., Walter, L., Streckfuß‐Bömeke, K., Guan, K., & Dressel, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125544 · Cited by 57
An eye to the future: Researchers debate best path for stem cell-derived therapies
Chakradhar, S. (2016) · Nature Medicine · doi:10.1038/nm0216-116 · Cited by 56
Achieving Efficient Manufacturing and Quality Assurance through Synthetic Cell Therapy Design
Lipsitz, Y. Y., Bedford, P., Davies, A. H., Timmins, N. E., & Zandstra, P. W. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.12.003 · Cited by 42
Assessing Commercial Opportunities for Autologous and Allogeneic Cell-Based Products
Smith, D. M. (2012) · Regenerative Medicine · doi:10.2217/rme.12.40 · Cited by 37
Deuse, T., Seifert, M., Phillips, N., Fire, A. Z., Tyan, D. B., Kay, M. A., Tsao, P. S., Hua, X., Velden, J., EIERMANN, T. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.020727 · Cited by 35
Self-citationMaking it personal: The prospects for autologous pluripotent stem cell-derived therapies
Blair, N. F., & Barker, R. A. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0057 · Cited by 22
Didié, M., Galla, S., Muppala, V., Dressel, R., & Zimmermann, W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00955 · Cited by 11
Maddaluno, M., MacRitchie, N. A., Grassia, G., Ialenti, A., Butcher, J. P., Garside, P., Brewer, J. M., & Maffia, P. (2014) · BioMed Research International · doi:10.1155/2014/949845 · Cited by 7
Cited by
Sorted by citations
The CD47-SIRPα Immune Checkpoint
Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 760
Treg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 746
Next-generation regulatory T cell therapy
Ferreira, L. M. R., Müller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 491
Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications
Doss, M. X., & Sachinidis, A. (2019) · Cells · doi:10.3390/cells8050403 · Cited by 486
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 451
Metadata
- Authors
- Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., Davis, M. M., Lanier, L. L., & Schrepfer, S.
- Affiliations
- University of California, San Francisco (US)
- Universität Hamburg (DE)
- University of North Carolina at Chapel Hill (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Schrepfer, Sonja
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2019-02-18
- Volume
- 37
- Issue
- 3
- Pages
- 252-258
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC6419516
- OpenAlex
- W2911604931
- Cited by
- 758
- References
- 31
- Citations by year
- 2026: 98 · 2025: 102 · 2024: 102 · 2023: 113 · 2022: 94 · 2021: 97 · 2020: 106 · 2019: 46
- FWCI
- 28.36
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-09-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL140236)
- National Institute of Mental Health (R01MH108179)
- National Institute of Allergy and Infectious Diseases (R01AI068129, R01AI111899, R01AI123010, U19AI057229)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- induced pluripotent stem cells, immune rejection, allogeneic transplantation, MHC mismatch, endothelial cells, smooth muscle cells, cardiomyocytes, immunosuppression-free transplantation
- MeSH terms
- Animals, Cell Differentiation, Graft Rejection, HLA Antigens, Humans, Transplantation, Homologous, Histocompatibility Antigens Class I, Myocytes, Cardiac, Mice, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
